Drug Profile
BVAC C
Alternative Names: BVAC-CLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Cellid Company
- Class Cancer vaccines; Vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Helper-inducer T-lymphocyte stimulants; Natural killer cell stimulants; Natural killer T cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cervical cancer
Most Recent Events
- 28 Sep 2022 BVAC C is still in phase II trial for Cervical cancer in South Korea (IV) (Cellid Company pipeline, September 2022)
- 30 Jun 2022 Cellid completes a phase I/IIa trial in Cervical cancer (Metastatic disease, Second-line therapy or greater) in South Korea (IV) (NCT02866006)
- 04 Jun 2021 Efficacy data from a phase I/IIa trial in Cervical cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)